BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial have?
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial has 209 citations in the OpenAlex counts ScholarIQ stores.
When was BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial published?
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial has 2024 year in the ScholarIQ index.
What is the open-access status of BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial?
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial has closed oa status in the ScholarIQ index.
What is the DOI of BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial?
The DOI for BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial is on the source record.
What is the PMID of BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial?
The PMID for BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial is on the source record.
What is the OpenAlex record for BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial?
The OpenAlex for BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial is on the source record.